A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus

M. W. Kline, C. V. Fletcher, A. T. Harris, K. D. Evans, R. C. Brundage, R. P. Remmel, N. R. Calles, S. B. Kirkpatrick, C. Simon

Research output: Contribution to journalArticle

49 Scopus citations

Abstract

Twelve children infected with the human immunodeficiency virus were treated orally with indinavir, stavudine, plus didanosine for 12 to 48 weeks. Therapy was limited in some cases by nonadherence, intolerance, toxicity, and virologic failure. Marked increases in CD4+ lymphocyte counts and decreases in plasma human immunodeficiency virus RNA concentrations suggest that the regimen has potent antiviral activity.

Original languageEnglish (US)
Pages (from-to)543-546
Number of pages4
JournalJournal of Pediatrics
Volume132
Issue number3 I
DOIs
StatePublished - 1998
Externally publishedYes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus'. Together they form a unique fingerprint.

  • Cite this